Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech
ACCESSWIRE
25 May 2021, 22:05 GMT+10
Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plus royalties for commercialized programs
Collaboration includes initial programs in respiratory disease and ophthalmology,
with opportunity to nominate additional programs
BOSTON, MA / ACCESSWIRE / May 25, 2
021 /
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin
® technology platform for respiratory diseases, cancer, and other indications, today announced it has entered into a multi-program research collaboration and license agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage Pieris propri
Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
Ribometrix, Inc., today announced a strategic collaboration with Genentech, a member of the Roche Group, to discover and develop novel RNA-targeted small molecule therapeutics against several targets. Ribometrix is focused on leveraging its RNA structural expertise and analytical capabilities to make the vast landscape of RNA, which is involved in a wide variety of disease processes, accessible to small molecule therapeutics. Ribometrixs platform uses multiple specialized technologies, including world-leading structural analytic capabilities, to identify 3D motifs in RNA molecules and then design small molecule candidates that bind to these motifs to produce a therapeutic effect.
Genentech Launches $1B+ RNA Collaboration with Ribometrix
Ribometrix has shown that several RNAs associated with disease contain structural pockets clefts and crevices (highlighted) that are amenable to targeting with small molecules. Genentech, a member of the Roche Group, will apply Ribometrix’s discovery platform to discover, develop and commercialize small molecule drug candidates against RNA targets, through a collaboration that could generate more than $1 billion for the Durham, NC-based company. [Ribometrix]
January 6, 2021
Ribometrix has shown that several RNAs associated with disease contain structural pockets clefts and crevices (highlighted) that are amenable to targeting with small molecules. Genentech, a member of the Roche Group, will apply Ribometrix’s discovery platform to discover, develop and commercialize small molecule drug candidates against RNA targets, through a collaboration that could generate more than $1 billion for the Durham, NC-based company. [Ri